GlassScriptPhysician profile
Ryan Joseph Daly
NPI 1356124432
$2,675.78
in general payments reported to CMS, 2019-2025
22 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.87 · 2023: $95.41 · 2024: $883 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $521.52 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $420.29 | 2023-2025 | |
| Abbvie INC. | $403.21 | 2023-2025 | |
| Glaxosmithkline, LLC. | $211.09 | 2024-2025 | Trelegy Ellipta, Nucala |
| Otsuka America Pharmaceutical, INC. | $161.47 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $149.43 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lundbeck LLC | $129.74 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $100.92 | 2024-2025 | Austedo Xr, Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.12 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $79.37 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Neurocrine Biosciences, INC. | $73.16 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.26 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $40.74 | 2025 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $36.08 | 2025 | Gemtesa |
| Boston Scientific Corporation | $33.17 | 2024 | Watchman Flx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $32.39 | 2025 | Omnipod |
| Dexcom, INC. | $30.51 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $28.34 | 2024 | |
| Medtronic, INC. | $23.44 | 2025 | Minimed 780g |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.84 | 2023 | Rexulti |
| Organon LLC | $17.20 | 2025 | Nexplanon |
| Phathom Pharmaceuticals, INC. | $10.49 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.